| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5537049 | Vaccine | 2017 | 9 Pages |
Abstract
Age-based WNV vaccination program targeting those at higher risk for severe disease is more cost-effective than universal vaccination. Annual variation in WNV disease incidence, QALY weights, and vaccine costs impact the cost effectiveness ratios.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Manjunath B. Shankar, J. Erin Staples, Martin I. Meltzer, Marc Fischer,